← Back to Search

Other

ZX-101A for Lymphoma

Phase 1 & 2
Waitlist Available
Research Sponsored by Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing a new drug, ZX-101A, to see if it is safe and effective in treating patients with relapsed or resistant blood cancers.

Eligible Conditions
  • Lymphoma
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Defining the recommended Phase 2 dose (RP2D) of ZX-101A.
Safety and tolerability of ZX-101A
Secondary outcome measures
Area under the plasma concentration of ZX-101A
Duration of response (DoR)
Half-life of ZX-101A
+5 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: ZX-101A Dose Level 5Experimental Treatment1 Intervention
5-times the SD of ZX-101A administered orally once daily in a 28-day cycle
Group II: ZX-101A Dose Level 4Experimental Treatment1 Intervention
4-times the SD of ZX-101A administered orally once daily in a 28-day cycle
Group III: ZX-101A Dose Level 3Experimental Treatment1 Intervention
3-times the SD of ZX-101A administered orally once daily in a 28-day cycle
Group IV: ZX-101A Dose Level 2Experimental Treatment1 Intervention
2-times the SD of ZX-101A administered orally once daily in a 28-day cycle
Group V: ZX-101A Dose Level 1Experimental Treatment1 Intervention
Starting dose (SD) of ZX-101A administered orally once daily in a 28-day cycle

Find a Location

Who is running the clinical trial?

Hangzhou Zenshine Pharmaceuticals Co., Ltd.Lead Sponsor
Xiaolin Qin, PhDStudy DirectorZenshine Pharmaceutical, Inc.
1 Previous Clinical Trials
70 Total Patients Enrolled
1 Trials studying Lymphoma
70 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
2021. "Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04504708.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top